Abstract：Objective: To investigate the relationship between the expression of serum soluble CD105 (S-CD105), vascular endothelial growth factor (VEGF), matrix metalloproteinase 9 (MMP9) and recurrence of non-small cell lung cancer (NSCLC) after radical operation. Methods: 102 patients with NSCLC treated in our hospital from September 2014 to October 2017 were selected as the study subjects, who were followed up for 2 years. They were divided into recurrence group (n=44) and non-recurrence group (n=52) based on the recurrence. Another 60 healthy persons were selected as the control group during the same period. The levels of serum S-CD105, VEGF and MMP9 were detected by ELISA, the changes of levels of serum S-CD105, VEGF and MMP9 were observed, the recurrence rates of patients with different levels of S-CD105, VEGF, MMP9S-CD105, VEGF and MMP9 were observed, and the predictive value of the expression of three factors for recurrence after NSCLC and the influencing factors were analyzed. Results: The levels of serum S-CD105, VEGF and MMP9 in the relapsed group were significantly higher than those in the non-relapsed group and the control group (P<0.05). The recurrence rate of patients with high expressions of serum S-CD105, VEGF and MMP9 was higher than that of patients with low expressions (P<0.05). MMP9 had the highest specificity but lower sensitivity in predicting recurrence of NSCLC, and AUC predicted by VEGF was the highest, and the sensitivity and specificity were slightly higher than those predicted by S-CD105. TNM stage, chemotherapy cycle, S-CD105, VEGF and MMP9 were independent risk factors for recurrence of NSCLC. Conclusion: Serum S-CD105, VEGF and MMP9 are highly expressed in patients with recurrent NSCLC, postoperative recurrence rate of patients with high expressions of the three factors is high. These three factors have certain predictive values for postoperative recurrence and are independent risk factors for postoperative recurrence.
李彦明, 郝雁冰, 杨继雷, 李传贵, 陈万生, 陈万生. 血清S-CD105 VEGF MMP9表达与非小细胞肺癌根治术后再复发的关系[J]. 河北医学, 2020, 26(8): 1281-1285.
LI Yanming, HAO Yanbing, YANG Jilei, et al. The Association Between the Expressions of Serum S-CD105 VEGF MMP9 and Recurrence of Non-small Cell Lung Cancer After Radical Operation. HeBei Med, 2020, 26(8): 1281-1285.
[1] Chen H, Chong W, Teng C, et al. The immune response-related mutational signatures and driver genes in non-small cell lung cancer[J]. Cancer Sci, 2019, 110(8):2348~2356. [2] Gong H, Wang Y, Han G, et al. Radiotherapy for oligometastatic tumor improved the prognosis of patients with non-small cell lung cancer (NSCLC)[J]. Thorac Cancer, 2019, 10(5):1136~1140. [3] Muchnik E, Loh KP, Strawderman M, et al. Immune checkpoint inhibitors in real-world treatment of older adults with non-small cell lung cancer[J].Am Geriatr Soc, 2019, 67(5):905~912. [4] 陈松耀, 缪娜波, 李展宇, 等.肿瘤组织中CD105标记的微血管密度对Ⅱ期结直肠癌预后价值的临床研究[J].消化肿瘤杂志(电子版), 2019, 11(3):201~211. [5] Li X, Wang X, Li Z, et al. Chemokine receptor 7 targets the vascular endothelial growth factor via the AKT/ERK pathway to regulate angiogenesis in colon cancer[J]. Cancer Med, 2019, 8(11):5327~5340. [6] Xia H, Jing H, Li Y, et al. Long noncoding RNA HOXD-AS1 promotes non-small cell lung cancer migration and invasion through regulating miR-133b/MMP9 axis[J]. Biomed Pharmacother, 2018, 106(1):156~162. [7] Moon SH, Kim J, Joung JG, et al. Correlations between metabolic texture features, genetic heterogeneity, and mutation burden in patients with lung cancer[J]. Eur Nucl Med Mol Imaging, 2019, 46(2):446~454. [8] 徐鲁荔.2014年湖北省肿瘤登记地区肺癌发病和死亡分析[J].中国肿瘤, 2019, 28(8):571~576. [9] Shi D, Che J, Yan Y, et al. Expression and clinical value of CD105 in renal cell carcinoma based on data mining in the cancer genome atlas[J]. Exp Ther Med, 2019, 17(6):4499~4505. [10] Patil BR, Bhat K, Somannavar P, et al. Comparison of immunohistochemical expression of vascular endothelial growth factor and CD105 in oral squamous cell carcinoma: Its correlation with prognosis[J].Cancer Res Ther, 2018, 14(2):421~427. [11] An X, Ge J, Guo H, et al. Overexpression of miR-4286 is an unfavorable prognostic marker in individuals with non-small cell lung cancer[J].Cell Biochem, 2019, 120(10):17573~17583. [12] 李晓平, 任开明, 张亮, 等.肿瘤坏死因子超家族15、血管内皮生长因子及生存素在非小细胞肺癌中的表达及其与远期生存时间的相关性[J].中华实验外科杂志, 2018, 35(10):1793~1796. [13] 刘烨, 高志海, 安燚, 等.结肠癌组织中转化生长因子-β1和缺氧诱导因子-1α及血管内皮生长因子的表达及临床意义[J].中国慢性病预防与控制, 2019, 27(5):352~355. [14] 陈明祥, 李杨.血清bFGF、VEGF和CEA表达水平对胃癌根治术后患者复发转移的预测研究[J].中华肿瘤防治杂志, 2018, 25(S1):12~13. [15] 周宁, 谭晓殊, 许婷婷, 等.RECK、MMP9蛋白在三阴性乳腺癌中的表达及与患者临床特征及预后的关系[J].癌症进展, 2019, 17(16):1942~1945.
2020, Vol. 26 
冀公网安备13080202000677号